Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from Candida albicans. 2017

Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
International Cooperation Base of Pesticide and Green Synthesis (Hubei), Key Laboratory of Pesticide & Chemical Biology (CCNU), Ministry of Education, Department of Chemistry, Central China Normal University , Wuhan 430079, China.

Class II fructose-1,6-bisphosphate aldolases (FBA-II) are attractive new targets for the discovery of drugs to combat invasive fungal infection, because they are absent in animals and higher plants. Although several FBA-II inhibitors have been reported, none of these inhibitors exhibit antifungal effect so far. In this study, several novel inhibitors of FBA-II from C. albicans (Ca-FBA-II) with potent antifungal effects were rationally designed by jointly using a specific protocols of molecular docking-based virtual screening, accurate binding-conformation evaluation strategy, synthesis and enzymatic assays. The enzymatic assays reveal that the compounds 3c, 3e-g, 3j and 3k exhibit high inhibitory activity against Ca-FBA-II (IC50 < 10 μM), and the most potential inhibitor is 3g, with IC50 value of 2.7 μM. Importantly, the compounds 3f, 3g, and 3l possess not only high inhibitions against Ca-FBA-II, but also moderate antifungal activities against C. glabrata (MIC80 = 4-64 μg/mL). The compounds 3g, 3l, and 3k in combination with fluconazole (8 μg/mL) displayed significantly synergistic antifungal activities (MIC80 < 0.0625 μg/mL) against resistant Candida strains, which are resistant to azoles drugs. The probable binding modes between 3g and the active site of Ca-FBA-II have been proposed by using the DOX (docking, ONIOM, and XO) strategy. To our knowledge, no FBA-II inhibitors with antifungal activities against wild type and resistant strains from Candida were reported previously. The positive results suggest that the strategy adopted in this study are a promising method for the discovery of novel drugs against azole-resistant fungal pathogens in the future.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005634 Fructose-Bisphosphate Aldolase An enzyme of the lyase class that catalyzes the cleavage of fructose 1,6-biphosphate to form dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. The enzyme also acts on (3S,4R)-ketose 1-phosphates. The yeast and bacterial enzymes are zinc proteins. (Enzyme Nomenclature, 1992) E.C. 4.1.2.13. Aldolase,Fructosediphosphate Aldolase,Aldolase A,Aldolase B,Aldolase C,Fructose 1,6-Bisphosphate Aldolase,Fructose 1,6-Bisphosphate Aldolase, Class II,Fructose 1-Phosphate Aldolase,Fructose Biphosphate Aldolase,Fructosemonophosphate Aldolase,1,6-Bisphosphate Aldolase, Fructose,Aldolase, Fructose 1,6-Bisphosphate,Aldolase, Fructose 1-Phosphate,Aldolase, Fructose Biphosphate,Aldolase, Fructose-Bisphosphate,Aldolase, Fructosediphosphate,Aldolase, Fructosemonophosphate,Fructose 1 Phosphate Aldolase,Fructose 1,6 Bisphosphate Aldolase,Fructose Bisphosphate Aldolase
D005635 Fructosediphosphates Diphosphoric acid esters of fructose. The fructose-1,6- diphosphate isomer is most prevalent. It is an important intermediate in the glycolysis process.
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics

Related Publications

Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
August 2013, Journal of agricultural and food chemistry,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
January 2018, In silico pharmacology,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
September 2011, Acta crystallographica. Section F, Structural biology and crystallization communications,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
September 2014, Acta crystallographica. Section F, Structural biology communications,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
January 1982, Methods in enzymology,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
November 2001, Acta crystallographica. Section D, Biological crystallography,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
April 2019, Heliyon,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
January 1977, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
January 2021, Journal of immunology research,
Xinya Han, and Xiuyun Zhu, and Zongqin Hong, and Lin Wei, and Yanliang Ren, and Fen Wan, and Shuaihua Zhu, and Hao Peng, and Li Guo, and Li Rao, and Lingling Feng, and Jian Wan
December 1984, Biochemistry,
Copied contents to your clipboard!